Innovation and industry evolution: A comment

Knowledge Accumulation and Industry Evolution: The Case of Pharma-Biotech

Volumn , Issue , 2006, Pages 146-160

  Galambos, Louis ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84928597255     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511493232.005     Document Type: Chapter

References (53)

1. Abramovitz, M., and P. A. David (2000), “American macroeconomic growth in the era of knowledge-based progress: the long-run perspective,” in S. L. Engerman and R. E. Gallman (eds.), The Cambridge Economic History of the United States, Vol. III, The Twentieth Century, Cambridge University Press, New York, 66–84.
2. Achilladelis, B., and N. Antonakis (2001), “The dynamics of technological innovation: the case of the pharmaceutical industry,” Research Policy, 30, 535–88.
3. Angell, M. (2004), “The truth about the drug companies,” New York Review of Books, 15 July.
4. Arora, A., and A. Gambardella (1998), “Evolution of industry structure in the chemical industry,” in A. Arora, R. Landau, and N. Rosenberg (eds.), Chemicals and Long-Term Economic Growth: Insights from the Chemical Industry, Wiley, New York, 379–413.
5. Balzat, M., and H. Hanusch (2004), “Recent trends in the research on national innovation systems,” Journal of Evolutionary Economics, 14, 197–210.
6. Bottazzi, G., G. Dosi, M. Lippi, F. Pammolli, and M. Riccaboni (2001), “Innovation and corporate growth in the evolution of the drug industry,” International Journal of Industrial Organization, 19 (7), 1161–87.
7. Caines, K., J. Bataringaya, L. Lush, G. Murindwa, and H. Njie (2003), Impact of Public–Private Partnerships Addressing Access to Pharmaceuticals in Low-Income Countries: Uganda Pilot Study, Global Forum for Health Research, Geneva.
8. Chandler, A. D., Jr. (1962), Strategy and Structure: Chapters in the History of the Industrial Enterprise, MIT Press, Cambridge, MA.
9. Chandler, A. D., (1977), The Visible Hand: The Managerial Revolution in American Business, Harvard University Press, Cambridge, MA.
10. Chandler, A. D., (1990), Scale and Scope: The Dynamics of Industrial Capitalism, Harvard University Press, Cambridge, MA.
11. Chandler, A. D., (2001), Inventing the Electronic Century: The Epic Story of the Consumer Electronics and Computer Industries, Free Press, New York.
12. Chandler, A. D., (2005), Shaping the Industrial Century: The Remarkable Story of the Evolution of the Modern Chemical and Pharmaceutical Industries, Harvard Business School Press, Boston.
13. Christensen, C. M. (1997), The Innovator’s Dilemma: When New Technologies Cause Great Firms to Fail, Harvard Business School Press, Boston.
14. Cockburn, I. M., and R. M. Henderson (1998), “Absorptive capacity, coauthoring behavior, and the organization of research in drug discovery,” Journal of Industrial Economics, 46 (2), 157–81.
15. Collins, J. C., and J. I. Porras (1994), Built to Last: Successful Habits of Visionary Companies, Harper Business, New York.
16. Collins, R. (1981), The Business Response to Keynes, 1929–1964, Columbia University Press, New York.
17. DiMasi, J. A., R. W. Hansen, H. G. Grabowski, and L. Lasagna (1995), “Research and development costs for new drugs by therapeutic category,” PharmacoEconomics, 7 (2), 152–69.
18. Distlerath, L., and G. Macdonald (2004), “TheAfrican comprehensiveHIV/AIDS partnerships – a new role for multinational corporations in global health policy,” Yale Journal ofHealth Policy, Law, and Ethics, 4 (1), 147–55.
19. Dosi, G., and R. R. Nelson (1994), “An introduction to evolutionary theories in economics,” Journal of Evolutionary Economics, 4, 153–72.
20. Eisenberg, R. S. (1996), “Public research and private development: patents and technology transfer in government-sponsored research,” Virginia Law Review, 82 (8), 1663–727.
21. Fagerberg, J. (2003), “Schumpeter and the revival of evolutionary economics: an appraisal of the literature,” Journal of Evolutionary Economics, 13, 125–59.
22. Galambos, L. (2000), “The U.S. corporate economy in the twentieth century,” in S. L. Engerman and R. E. Gallman (eds.), The Cambridge Economic History of the United States, Vol. III, The Twentieth Century, Cambridge University Press, New York, 927–67.
23. Galambos, L., and J. Pratt (1988), The Rise of the Corporate Commonwealth: United States Business and Public Policy in the Twentieth Century, Basic Books, New York.
24. Galambos, L., and J. L. Sturchio (1998), “Pharmaceutical firms and the transition to biotechnology: a study in strategic innovation,” Business History Review, 72 (Summer), 250–78.
25. Gambardella, A. (1995), Science and Innovation: The US Pharmaceutical Industry During the 1980s, Cambridge University Press, Cambridge.
26. Gambardella, A., L. Orsenigo, and F. Pammolli (2000), “Benchmarking the competitiveness of the European pharmaceutical industry,” European Commission, Brussels.
27. Grabowski, H. G., and J. Vernon (2000), “The determinants of pharmaceutical research and development expenditures,” Journal of Evolutionary Economics, 10, 201–15.
28. Hammer, M., and J. Champy (1993), Reengineering the Corporation: A Manifesto for Business Revolution, Harper Business, New York.
29. Hara, T. (2003), Innovation in the Pharmaceutical Industry: The Process of Drug Discovery and Development, Edward Elgar, Cheltenham.
30. Henderson, R. M., L. Orsenigo, and G. Pisano (1999), “The pharmaceutical industry and the revolution in molecular biology: exploring the interactions between scientific, institutional, and organizational change,” in D. C. Mowery and R. R. Nelson (eds.), Sources of Industrial Leadership: Studies of Seven Industries, Cambridge University Press, Cambridge, 267–311.
31. Hodgson, G. M. (1998), The Foundations of Evolutionary Economics, 1890–1973, Edward Elgar, Northhampton, MA.
32. Lacetera, N., and L. Orsenigo (2001), “Political Regimes, Technological Regimes and Innovation in the Evolution of the Pharmaceutical Industry in theUSA and in Europe,” paper presented at Conference on Evolutionary Economics, Johns Hopkins University, Baltimore, 30–31 March.
33. Landau, R., B. Achilladelis, and A. Scriabine (1999), Pharmaceutical Innovation: Revolutionizing Human Health, Chemical Heritage Press, Philadelphia.
34. Maddison, A. (1995), Monitoring the World Economy, 1820–1992, Development Centre, Organisation for Economic Co-operation and Development, Paris.
35. Ministry of State President, National AIDS Coordinating Agency (2003), Status of the 2002 National Response to the UNGASS Declaration of Commitment on HIV/AIDS, Country Report, Government of Botswana, Gaborone.
36. Mowery, D. C., and R. R. Nelson (eds.) (1999), Sources of Industrial Leadership: Studies of Seven Industries, Cambridge University Press, Cambridge.
37. Murmann, J. P. (2003), Knowledge and Competitive Advantage: The Coevolution of Firms, Technology, and National Institutions, Cambridge University Press, New York.
38. Nelson, R. R. (ed.) (1993), National Innovation Systems: A Comparative Analysis, Oxford University Press, New York.
39. Nelson, R. R. (1995), “Recent evolutionary theorizing about economic change,” Journal of Economic Literature, 33, 48–90.
40. Nelson, R. R., and S. G. Winter (1982), An Evolutionary Theory of Economic Change, Harvard University Press, Cambridge, MA.
41. Orsenigo, L., F. Pammolli, and M. Riccaboni (2001), “Technological change and network dynamics: lessons from the pharmaceutical industry,” Research Policy, 30, 485–508.
42. Peters, T. J., and R. H. Waterman, Jr. (1982), In Search of Excellence: Lessons from America’s Best-Run Companies, Harper, New York.
43. Piore, M. J., and C. F. Sabel (1984), The Second Industrial Divide: Possibilities for Prosperity, Basic Books, New York.
44. Schumpeter, J. A. (1934; Galaxy edn., 1961), The Theory of Economic Development: An Inquiry into Profits, Capital, Credit, Interest, and the Business Cycle, Oxford University Press, New York.
45. Schumpeter, J. A. (1942; 3rd edn., 1950) Capitalism, Socialism, and Democracy, Harper, New York.
46. Schumpeter, J. A. (1951; Meridian edn., 1958), Imperialism; Social Classes, Meridian Books, New York.
47. Stein, H. (1969), The Fiscal Revolution in America, University of Chicago Press, Chicago.
48. Stolper, W. F. (1994), Joseph Alois Schumpeter: The Public Life of a Private Man, Princeton University Press, Princeton, NJ.
49. Tichy, N. M., and E. Cohen (1997), The Leadership Engine: How Winning Companies Build Leaders at Every Level, Harper Collins, New York.
50. UNAIDS (2003), Accelerating Action Against AIDS in Africa, Joint United Nations Programme on HIV/AIDS, Geneva.
51. Vagelos, R., and L. Galambos (2004), Medicine, Science and Merck, Cambridge University Press, Cambridge.
52. Zelizer, J. E. (1998), Taxing America: Wilbur D. Mills, Congress, and the State, 1945–1975, Cambridge University Press, New York.
53. Zucker, L. G., and M. R. Darby (1995), Virtuous Circles of Productivity: Star Bioscientists and the Institutional Transformation of Industry, Working Paper no. 5342, National Bureau of Economic Research, Cambridge, MA.